The Cancer Monoclonal Antibodies is predicted to reach USD $45 Billion by 2020 with a CAGR of 11.2% according to Market Data Forecast report

The Cancer Monoclonal Antibodies is predicted to reach USD $45 Billion by 2020 with a CAGR of 11.2% according to Market Data Forecast report

ID: 191 | April 2018 | Region: Global


The Monoclonal Antibodies Market report published by Market Data Forecast provides a detailed account of the Market Trends via Customized Research presented as Strategic Analyses, Company Profiles, Competitive Landscape, etc. According to the report the Monoclonal Antibodies Market is estimated to be $27 USD billion in 2015 and predicted to rise to $ 45 USD billion with a CAGR of 11.2%. The market is segmented by application (Liver, Breast, Blood, Brain, Hodgkins and Non-Hodgkins lymphoma, Colorectal, leukaemia and others), type (murine antibodies, chimeric and humanised antibodies and fully humanized antibodies), Conjugate Cancer Therapies (Radioimmunotherapy, Immunoliposome, ADEPT, Immunocytokines and others). Further the market is also geographically segmented into North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa.

Increased prevalence of cancer is the key driver for the market. With the dramatic increase in number of cancer cases, pharmaceuticals companies started investing in monoclonal antibodies market. Increased investment in R&D of genomic studies, technological evolvement in target gene selection and genetic sequencing, specificity of monoclonal antibodies to target only the cancer cells without effecting the normal ones are the factors driving the growth of the market. The market is expected to grow at a lucrative rate in the next 5 years with the presence of highly strong products in the pipeline. However factors like high development cost, stringent guidelines, and longer durations required for research & development and clinical trials of antibodies are restraining the growth of the market.

The Global Monoclonal Antibodies market is geographically classified as North America, Europe, Asia-Pacific, Middle-East & Africa and Latin America. North America currently enjoys the major share in the market. The developing economies in Middle-East & Africa and Asia-Pacific are believed to grow at a faster rate owing to its untapped potential, increasing awareness among individuals, rising disposable income and increased investment in research & development.

The highly customizable nature of the monoclonal antibodies are attracting various organizations, research institutes and multinational companies to use it as a tool to cure cancer. The major players in the Cancer Monoclonal Antibodies Market are Amgen, Genmab, glaxosmithkline, Bristol Myers Squibb, Roche, Eli Lilly, Immunogen, Novartis, Seattle Genetics and Spectrum Pharmaceuticals.

Browse through the full report at “http://www.marketdataforecast.com/market-reports/global-cancer-monoclonal-antibodies-market-185/” and checkout our recent reports in the Pharmaceuticals category at “http://www.marketdataforecast.com/research-reports/healthcare/pharmaceuticals-1/”. For more insights and up-to-date industry news don’t forget subscribing to our newsletters.

 

 

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.